Eliminating the Public Health Problem of Hepatitis B and C in the United States PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Eliminating the Public Health Problem of Hepatitis B and C in the United States PDF full book. Access full book title Eliminating the Public Health Problem of Hepatitis B and C in the United States by National Academies of Sciences, Engineering, and Medicine. Download full books in PDF and EPUB format.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187
Get Book Here
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187
Get Book Here
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9789241549981
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
Author: Mitchell L. Shiffman
Publisher: Springer Science & Business Media
ISBN: 1461411920
Category : Medical
Languages : en
Pages : 333
Get Book Here
Book Description
Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.
Author: Angelos Hatzakis
Publisher: Springer Nature
ISBN: 3030677621
Category : Medical
Languages : en
Pages : 219
Get Book Here
Book Description
This volume provides the reader with a detailed overview of the current state-of-the art approach of Hepatitis C management. It reviews the course of action in handling of chronic Hepatitis C patients with various HCV genotypes and treats special cases such as acute hepatitis, transplant and renal patients as well as people who inject drugs. The two volume work on Hepatitis C introduces to the topic by reviewing virology, diagnosis, epidemiology, prevention, management and elimination of HCV. The book provides a valuable source at full length for researchers and clinicians working on Hepatitis C.
Author: World Health Organization
Publisher:
ISBN: 9789241548557
Category : Medical
Languages : en
Pages : 114
Get Book Here
Book Description
Individuals who donate their blood provide a unique and precious gift in an act of human solidarity. In order to donate blood, prospective donors should be in good health and free from any infections that can be transmitted through transfusion. Most blood donors perceive themselves to be healthy, but some are unsuitable to donate blood due to the potential risk of compromising or worsening their own health or the risk of transmission of infections to patients. Blood transfusion services (BTS) have a duty of care towards blood donors as well as to the recipients of transfusion. This duty of care extends to prospective donors who are deferred from donation--whether on a temporary or permanent basis--as well as those who donate blood and are subsequently found to have unusual or abnormal test results. BTS have a responsibility to confirm test results and provide information, counseling and support to enable these individuals to understand and respond to unexpected information about their health or risk status. Counseling is part of the spectrum of care that a BTS should be able to provide to blood donors--including referral to medical practitioners or specialist clinical services. Pre-donation counseling was recognized as one element of the strategy to reduce and, if possible, prevent the donation of blood by individuals who might be at risk for HIV and other TTI including hepatitis B and C viruses as well as to inform the donor of the donation process and testing of blood for HIV. Post-donation counseling was acknowledged to be a necessary element of donor management as an adjunct to informing donors of unusual or abnormal test results. Blood donor counseling by trained specialist staff is now considered to be a key component of the blood system in most countries with a well-developed blood transfusion service. It may be required at a number of stages in the blood donation process or following blood screening and should be available at any point at which the BTS has an interface with donors. In many countries, however, blood donor counseling is not yet available in a structured way. Blood Donor Counselling: Implementation Guidelines has therefore been developed to provide guidance to blood transfusion services that have not yet established donor counseling programs.
Author: Lucinda K. Porter, RN
Publisher: Demos Medical Publishing
ISBN: 1617051748
Category : Health & Fitness
Languages : en
Pages : 248
Get Book Here
Book Description
Hepatitis C is the most common blood-borne virus in the U.S. The Centers for Disease Control and Prevention estimate that 3.2 million Americans are chronically infected with the chronic hepatitis C virus (HCV). Treatment for HCV is long, sometimes lasting a year or more with success rate currently around 50%. And the medications often cause incapacitating side effects. Two new medications introduced in 2011 are showing success rates of 75 to 80%. However these new medications are taken with existing HCV drugs and include and intensify the side effects. Hepatitis C Treatment One Step at a Time provides the practical advice and daily inspiration you need to help you successfully make it through hepatitis C (HCV) treatment. Deciding to undergo hepatitis C treatment is one of the bravest and most important steps toward health youíll ever make. As a former Stanford nurse in the HCV field and a patient who was treated twice for HCV, Lucinda K. Porter understands how physically and emotionally challenging treatment can be. In Hepatitis C One Step at a Time, she provides entries for each day of treatment, offering you a daily dose of relief, encouragement, and tips to help you stay on treatment. From dealing with fatigue and nausea to nosy co-workers and lab results, Porter provides everything you need to know to ease the process, including how to: Prepare for treatment, mentally, physically, and financially Manage side effects Set up a support system Keep your spirits up with daily inspiration and humor Celebrate your strength and acknowledge your milestones Find additional community and up-to-date information with an extensive resources section
Author: Mitchell L. Shiffman
Publisher: Springer
ISBN: 9781461411932
Category : Medical
Languages : en
Pages : 332
Get Book Here
Book Description
Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.
Author: Paul J. Thuluvath
Publisher: JHU Press
ISBN: 1421417588
Category : Health & Fitness
Languages : en
Pages : 301
Get Book Here
Book Description
Vital and hopeful information for people suffering from hepatitis C, an often chronic—and sometimes deadly—disease of the liver. The liver is the body's workhorse. It makes proteins and bile, processes fats, and detoxifies drugs and alcohol. The liver is a resilient organ, but it is susceptible to damage from a number of sources, including viral infections. Such infections cause inflammation of the liver, called hepatitis. This book is a comprehensive guide to hepatitis C, which affects about 3 percent of the world's population—3 to 4 million people in the United States alone. Some people with acute hepatitis C infection will be cured without any treatment, but when hepatitis C becomes chronic it may cause cirrhosis, liver cancer, and death. Hepatitis C is transmitted from an infected person to an uninfected person by sharing drug-injecting equipment, snorting cocaine, having sex, or getting a blood transfusion or organ transplant. It can be spread by getting a tattoo with unsterile equipment. In rare cases, women with hepatitis C transmit the virus to their infants. World-renowned gastroenterologist and liver specialist Dr. Paul J. Thuluvath provides detailed information about the disease and its diagnosis and management, including dramatically improved treatments that have recently emerged. Dr. Thuluvath answers common and uncommon questions about hepatitis C and liver disease, including How is hepatitis C spread? Who should be tested—and what tests diagnose hepatitis C and other liver diseases? What are the symptoms of acute liver disease? What are the symptoms and complications of chronic liver disease? What are the complications of cirrhosis (scarring of the liver)? How does hepatitis C affect other organs in the body? What treatment options are available, and what side effects might they have? How is early liver cancer diagnosed and treated? When is liver transplantation needed, and how does it work? Dr. Thuluvath provides the latest information on new interferon-free regimens, which have shown a cure rate of more than 90% in people with specific genotypes—and which avoid the distressing side effects of interferon therapy. He discusses hepatitis C in children as well as complementary and alternative medicine. Published while revolutionary changes are taking place in the treatment of hepatitis C, this authoritative guide will become the preferred reference for people with hepatitis C and their families.
Author: Nancy Reau
Publisher: Oxford University Press
ISBN: 0190238291
Category : Medical
Languages : en
Pages : 201
Get Book Here
Book Description
Fueled in part by the opioid epidemic, the number of reported hepatitis C virus infections tripled in the United States between 2010 and 2015. As new infections continue to mount, new therapies have produced seismic changes in how HCV is treated clinically, leaving a gap between the most current clinical guidance and the ongoing demands of patient care. The New Hepatitis C is a current and essential review of HCV's epidemiology, diagnosis, and clinical approaches -- a clinician's guidebook for navigating everything from screening to treatment. Acute and chronic HCV are addressed, as are important new treatment options for HCV, management of side effects, and a convenient summary of clinical trials on the treatment of chronic hepatitis C. Updated to detail the standards of care that will define the next decade of HCV management, this evidence-based volume is an essential clinical reference for to any practitioner in gastroenterology, hepatology, infectious disease, transplant, or internal medicine.
Author: Martina Smolic
Publisher: BoD – Books on Demand
ISBN: 9535135635
Category : Medical
Languages : en
Pages : 240
Get Book Here
Book Description
In the past few years, remarkable progress has been made in our understanding of HCV biology, pathogenesis of infection, and structure-function relationships. This has led to quantum advances in clinical efficacy and tolerability. Yet, in spite of this amazing progress, there remain obstacles to widespread successful treatment. These issues include biological failures even with direct-acting agents, lack of options for individual with organ failures, drug-drug interactions, access to medications either due to lack of availability or affordability, and psychiatric and social issues. These problems are likely to remain in the future. Therefore, this book has been created by distinguished faculties from around the world to address the progress in our understanding of HCV infection and to review new treatment options, limitations, and accessibility of new therapeutic options.
